EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
The drug candidate improved progression-free survival in patients, it said.
Breast Cancer Drugs Market Size is Projected to Reach USD 80.34 Billion by 2033, Growing at a CAGR of 8.90%: Straits Research
The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...
GlobalData on MSN7d
AstraZeneca reports positive outcomes from breast cancer combo therapy trial
AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...
BioSpace2d
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
AstraZeneca to bring innovative medicines faster to India, says MD Panchal
The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...
PharmExec6d
AstraZeneca’s Camizestrant Shows Survival Improvement for HR-Positive, HER2-Negative Advanced Breast Cancer with Emergent ESR1 Mutations
The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...
Fierce Biotech8d
AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
PharmExec2d
Follow-Up Results from OlympiA Trial Highlight 28% Mortality Benefit with Lynparza in gBRCAm Breast Cancer
Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses how results of the trial compare with other treatments for gBRCAm HER2-negative high-risk early breast cancer.
AstraZeneca breast cancer drug shows positive results, shares up
Bank of America analysts estimate a peak sales potential of $6 billion for camizestrant across the SERENA-6 and SERENA-4 ...
Wall Street Journal8d
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...